

Review of TA424; Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer

Decision

The guidance remains relevant and an update is not needed.

Background

TA424 was published in December 2016 (see appendix A) and scheduled to be considered for review in 2019.

Stakeholders were asked whether the guidance is still relevant and whether there is new evidence that would affect the recommendations (see appendix B).

Based on the information received, we found nothing new that affects the existing recommendations. The guidance remains relevant and an update is not needed. This may change if NICE becomes aware of new evidence that would make it reconsider.

Decision paper sign off

Jennifer Prescott – Programme Director, Planning and Operations

20 May 2020

Contributors to this paper

Project Manager: Charlotte Downing

Appendix A – Information from existing guidance

Original remit

To appraise the clinical and cost effectiveness of pertuzumab within its marketing authorisation for the neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer.

Current guidance

1.1 Pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2)-positive breast cancer; that is, in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is recommended only if the company provides pertuzumab with the discount agreed in the patient access scheme.

Appendix B – Stakeholders asked to comment

Stakeholders who agree that the guidance should remain unchanged

- Breast Cancer Now
- Roche Products Ltd

No response received from

- Against Breast Cancer
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Association of Anaesthetists of Great Britain and Ireland
- Association of Breast Surgery
- Association of Cancer Physicians
- Association of Surgeons of Great Britain & Ireland
- Black Health Agency
- Board of Community Health Councils in Wales
- Breast Cancer Care
- Breast Cancer Hope
- Breast Cancer Research Trust
- Breast Cancer UK
- British Association of Surgical Oncology
- British Geriatrics Society
- British Institute of Radiology
- British National Formulary
- British Psychosocial Oncology Society
- Cancer Black Care
- Cancer Equality
- Cancer Research UK
- Care Quality Commission
- Cochrane Breast Cancer Group

- Department of Health and Social Care
- Department of Health, Social Services and Public Safety for Northern Ireland
- Genomics England
- Healthcare Improvement Scotland
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Institute of Cancer Research
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie
- Medicines and Healthcare Products Regulatory Agency
- MRC Clinical Trials Unit
- Muslim Council of Britain
- National Association of Primary Care
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- NHS England and NHS Improvement
- NHS Oxfordshire CCG
- NHS Swindon CCG
- Pro-Cancer Research Fund
- Public Health England
- Public Health Wales
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists

- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Scottish Medicines Consortium
- Society and College of Radiographers
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Welsh Government
- Welsh Health Specialised Services Committee
- Women's Health Concern